[{"id":"8fdc7448-fd08-4efe-a0dd-3b2c163d7e37","acronym":"LIBRETTO-432","url":"https://clinicaltrials.gov/study/NCT04819100","created_at":"2021-03-26T14:52:36.044Z","updated_at":"2025-02-25T13:40:25.498Z","phase":"Phase 3","brief_title":"A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT04819100 - LIBRETTO-432","lead_sponsor":"Eli Lilly and Company","biomarkers":" RET","pipe":" | ","alterations":" RET fusion","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retevmo (selpercatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 12/20/2021","start_date":" 12/20/2021","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 08/01/2032","study_completion_date":" 08/01/2032","last_update_posted":"2025-02-21"},{"id":"9272430e-eab6-4fc0-8844-69d711337ecc","acronym":"ENDURE","url":"https://clinicaltrials.gov/study/NCT04892953","created_at":"2021-05-19T15:52:50.047Z","updated_at":"2025-02-25T13:40:30.743Z","phase":"Phase 2","brief_title":"Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy","source_id_and_acronym":"NCT04892953 - ENDURE","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • ALK • MET • RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement","tags":["EGFR • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 07/07/2021","start_date":" 07/07/2021","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-21"},{"id":"d9249df0-7324-4379-b412-dbfbc6b5d9e8","acronym":"NAUTIKA1","url":"https://clinicaltrials.gov/study/NCT04302025","created_at":"2021-01-18T20:51:55.005Z","updated_at":"2025-02-25T13:40:05.730Z","phase":"Phase 2","brief_title":"A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04302025 - NAUTIKA1","lead_sponsor":"Genentech, Inc.","biomarkers":" PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12","tags":["PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Cotellic (cobimetinib) • Gavreto (pralsetinib) • divarasib (RG6330)"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 03/06/2029","study_completion_date":" 03/06/2029","last_update_posted":"2025-02-21"},{"id":"63b7f842-7dbd-4050-9b6c-f6c0d81db8df","acronym":"(MARGARET)","url":"https://clinicaltrials.gov/study/NCT04683250","created_at":"2021-01-19T20:47:05.192Z","updated_at":"2025-02-25T14:02:08.938Z","phase":"Phase 1/2","brief_title":"Study of RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities","source_id_and_acronym":"NCT04683250 - (MARGARET)","lead_sponsor":"Taiho Pharmaceutical Co., Ltd.","biomarkers":" RET","pipe":" | ","alterations":" RET fusion","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vepafestinib (TAS0953/HM06)"],"overall_status":"Recruiting","enrollment":" Enrollment 202","initiation":"Initiation: 12/16/2020","start_date":" 12/16/2020","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2025-02-14"},{"id":"e3328e0d-a58a-4276-b607-b9374b9c681f","acronym":"AcceleRET Lung","url":"https://clinicaltrials.gov/study/NCT04222972","created_at":"2021-01-18T14:26:40.385Z","updated_at":"2025-02-25T16:37:43.151Z","phase":"Phase 3","brief_title":"A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT04222972 - AcceleRET Lung","lead_sponsor":"Hoffmann-La Roche","biomarkers":" RET","pipe":" | ","alterations":" RET fusion","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • Gavreto (pralsetinib)"],"overall_status":"Completed","enrollment":" Enrollment 223","initiation":"Initiation: 07/24/2020","start_date":" 07/24/2020","primary_txt":" Primary completion: 01/27/2025","primary_completion_date":" 01/27/2025","study_txt":" Completion: 01/27/2025","study_completion_date":" 01/27/2025","last_update_posted":"2025-02-06"},{"id":"903e5cab-7626-44c4-a016-54d2f4cf78c1","acronym":"LIBRETTO-431","url":"https://clinicaltrials.gov/study/NCT04194944","created_at":"2021-01-18T20:26:38.725Z","updated_at":"2025-02-25T17:30:06.532Z","phase":"Phase 3","brief_title":"A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04194944 - LIBRETTO-431","lead_sponsor":"Eli Lilly and Company","biomarkers":" RET","pipe":" | ","alterations":" RET fusion","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Retevmo (selpercatinib) • pemetrexed"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 261","initiation":"Initiation: 02/17/2020","start_date":" 02/17/2020","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-01-30"},{"id":"242a00a6-2e7d-4b18-8a4a-57905c77b105","acronym":"Lung-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT05364645","created_at":"2022-05-06T18:55:15.353Z","updated_at":"2024-07-02T16:34:27.438Z","phase":"Phase 2","brief_title":"Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05364645 - Lung-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • KRAS • BRAF • ALK • MET • RET • ROS1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive","tags":["EGFR • KRAS • BRAF • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Retevmo (selpercatinib) • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 07/25/2022","start_date":" 07/25/2022","primary_txt":" Primary completion: 06/27/2023","primary_completion_date":" 06/27/2023","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2024-06-11"},{"id":"8a3d3d41-a452-48ff-8178-8d754ba2fbf3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05170204","created_at":"2021-12-27T15:54:25.891Z","updated_at":"2024-07-02T16:34:59.196Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05170204","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1 • RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK fusion • ROS1 fusion","tags":["PD-L1 • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Gavreto (pralsetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 06/17/2029","primary_completion_date":" 06/17/2029","study_txt":" Completion: 04/14/2035","study_completion_date":" 04/14/2035","last_update_posted":"2024-06-04"},{"id":"ba697a0c-0213-4400-8a69-554239875d35","acronym":"LUNG-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT04268550","created_at":"2021-01-18T14:26:41.644Z","updated_at":"2024-07-02T16:34:59.356Z","phase":"Phase 2","brief_title":"Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)","source_id_and_acronym":"NCT04268550 - LUNG-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • KRAS • BRAF • ALK • MET • RET • ROS1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive","tags":["EGFR • KRAS • BRAF • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retevmo (selpercatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 04/08/2020","start_date":" 04/08/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-06-04"},{"id":"659f704a-33f9-4ece-9a3f-ade7e3e42f5c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06109558","created_at":"2023-10-31T18:13:38.814Z","updated_at":"2024-07-02T16:35:00.090Z","phase":"Phase 1/2","brief_title":"The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC","source_id_and_acronym":"NCT06109558","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR • MET • RET","pipe":" | ","alterations":" MET amplification • RET fusion • EGFR T790M negative","tags":["EGFR • MET • RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • RET fusion • EGFR T790M negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/31/2023","start_date":" 12/31/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 07/30/2027","study_completion_date":" 07/30/2027","last_update_posted":"2024-05-30"},{"id":"ea2426dc-fd65-4541-b437-a3fa2dace5ba","acronym":"Promise","url":"https://clinicaltrials.gov/study/NCT06081907","created_at":"2023-10-14T01:13:10.291Z","updated_at":"2024-07-02T16:35:00.048Z","phase":"Phase 1/2","brief_title":"The Efficacy and Safety of IBI363 in Solid Tumors","source_id_and_acronym":"NCT06081907 - Promise","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR • HER-2 • PD-L1 • BRAF • ALK • RET • CD73 • NTRK","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • RET fusion • ALK fusion • ALK mutation","tags":["EGFR • HER-2 • PD-L1 • BRAF • ALK • RET • CD73 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • RET fusion • ALK fusion • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Lenvima (lenvatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 12/25/2023","start_date":" 12/25/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2024-05-30"},{"id":"f0da2c69-063d-412e-8403-ded1fd245a6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05845671","created_at":"2023-05-06T15:04:41.894Z","updated_at":"2024-07-02T16:35:04.160Z","phase":"Phase 1/2","brief_title":"Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations","source_id_and_acronym":"NCT05845671","lead_sponsor":"University of Colorado, Denver","biomarkers":" RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK fusion • ROS1 fusion","tags":["RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 07/11/2023","start_date":" 07/11/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2024-05-13"},{"id":"74a856b5-259a-4d5c-9166-0007d61a1cb7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05570825","created_at":"2022-10-07T15:08:08.992Z","updated_at":"2024-07-02T16:35:05.631Z","phase":"Phase 2","brief_title":"SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05570825","lead_sponsor":"University of Washington","biomarkers":" PD-L1 • ALK • RET • ROS1","pipe":" | ","alterations":" PD-L1 expression • RET fusion • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement","tags":["PD-L1 • ALK • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • RET fusion • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SX-682 • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/06/2023","start_date":" 04/06/2023","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-05-07"},{"id":"e3283371-d5d3-4a68-bf39-709bf00315cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT05701787","created_at":"2023-01-27T16:00:02.113Z","updated_at":"2024-07-02T16:35:09.119Z","phase":"","brief_title":"Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations","source_id_and_acronym":"NCT05701787","lead_sponsor":"Shanghai Chest Hospital","biomarkers":" EGFR • KRAS • BRAF • ALK • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • RET fusion • ALK fusion • ROS1 fusion • KRAS G12 • ALK-ROS1 fusion • NTRK fusion","tags":["EGFR • KRAS • BRAF • ALK • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • RET fusion • ALK fusion • ROS1 fusion • KRAS G12 • ALK-ROS1 fusion • NTRK fusion"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 01/01/2019","start_date":" 01/01/2019","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2024-04-17"},{"id":"592ebddd-dcd6-4b4f-ad61-a8f732fba350","acronym":"ARROW","url":"https://clinicaltrials.gov/study/NCT03037385","created_at":"2021-01-17T17:13:27.011Z","updated_at":"2024-07-02T16:35:10.042Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","source_id_and_acronym":"NCT03037385 - ARROW","lead_sponsor":"Hoffmann-La Roche","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET mutation • RET rearrangement","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET mutation • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gavreto (pralsetinib)"],"overall_status":"Completed","enrollment":" Enrollment 589","initiation":"Initiation: 03/17/2017","start_date":" 03/17/2017","primary_txt":" Primary completion: 03/21/2024","primary_completion_date":" 03/21/2024","study_txt":" Completion: 03/21/2024","study_completion_date":" 03/21/2024","last_update_posted":"2024-04-11"},{"id":"a9ff4f76-2282-4d1f-9d45-07b786992ee1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05241834","created_at":"2022-02-16T18:53:36.129Z","updated_at":"2024-07-02T16:35:12.547Z","phase":"Phase 1","brief_title":"A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment","source_id_and_acronym":"NCT05241834","lead_sponsor":"Eli Lilly and Company","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LOXO-260"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 03/23/2022","start_date":" 03/23/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-27"},{"id":"84dc749a-0183-451c-8fd6-1c9e5b7e76b1","acronym":"LIBRETTO-001","url":"https://clinicaltrials.gov/study/NCT03157128","created_at":"2021-01-17T17:11:02.877Z","updated_at":"2024-07-02T16:35:16.573Z","phase":"Phase 1/2","brief_title":"A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)","source_id_and_acronym":"NCT03157128 - LIBRETTO-001","lead_sponsor":"Loxo Oncology, Inc.","biomarkers":" RET","pipe":" | ","alterations":" RET fusion","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retevmo (selpercatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 875","initiation":"Initiation: 05/02/2017","start_date":" 05/02/2017","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2024-03-04"},{"id":"1cd4bf5f-edfe-4d2a-b079-73a5000d620a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05225259","created_at":"2022-02-05T18:29:52.250Z","updated_at":"2024-07-02T16:35:17.299Z","phase":"","brief_title":"Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor","source_id_and_acronym":"NCT05225259","lead_sponsor":"Eli Lilly and Company","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LOXO-260"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-02-28"},{"id":"32e67e72-a7dc-4ce5-9a04-0d11b361ae23","acronym":"","url":"https://clinicaltrials.gov/study/NCT05675605","created_at":"2023-01-09T15:59:22.674Z","updated_at":"2024-07-02T16:35:21.856Z","phase":"Phase 1/2","brief_title":"A Study of TY-1091 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05675605","lead_sponsor":"TYK Medicines, Inc","biomarkers":" RET","pipe":" | ","alterations":" RET fusion","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TY-1091"],"overall_status":"Recruiting","enrollment":" Enrollment 248","initiation":"Initiation: 04/24/2023","start_date":" 04/24/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-01-30"},{"id":"652c5256-d9cf-4341-a41c-dd696f4d2fa3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05024929","created_at":"2021-08-27T12:53:01.955Z","updated_at":"2024-07-02T16:35:23.047Z","phase":"","brief_title":"Targeted Therapy to Increase RAI Uptake in Metastatic DTC","source_id_and_acronym":"NCT05024929","lead_sponsor":"Children's Hospital of Philadelphia","biomarkers":" BRAF • ALK • RET • NTRK","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • RET fusion • ALK fusion • ALK mutation • BRAF fusion • NTRK fusion","tags":["BRAF • ALK • RET • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • RET fusion • ALK fusion • ALK mutation • BRAF fusion • NTRK fusion"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/16/2021","start_date":" 07/16/2021","primary_txt":" Primary completion: 02/01/2031","primary_completion_date":" 02/01/2031","study_txt":" Completion: 02/01/2033","study_completion_date":" 02/01/2033","last_update_posted":"2024-01-18"},{"id":"499178b3-c7bc-4839-8508-0d08c3db9fb9","acronym":"POSEIDON","url":"https://clinicaltrials.gov/study/NCT04322591","created_at":"2021-01-18T14:26:42.526Z","updated_at":"2024-07-02T16:35:25.104Z","phase":"","brief_title":"Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial","source_id_and_acronym":"NCT04322591 - POSEIDON","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET positive","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET positive"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 03/24/2020","start_date":" 03/24/2020","primary_txt":" Primary completion: 12/24/2024","primary_completion_date":" 12/24/2024","study_txt":" Completion: 03/24/2025","study_completion_date":" 03/24/2025","last_update_posted":"2023-12-27"},{"id":"fa1b90d0-8c28-4ace-9d81-b327e5b1b6dc","acronym":"DARWIN II","url":"https://clinicaltrials.gov/study/NCT02314481","created_at":"2021-01-18T10:57:50.535Z","updated_at":"2024-07-02T16:35:27.240Z","phase":"Phase 2","brief_title":"Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity","source_id_and_acronym":"NCT02314481 - DARWIN II","lead_sponsor":"University College, London","biomarkers":" HER-2 • BRAF • ALK • RET","pipe":" | ","alterations":" HER-2 amplification • BRAF V600 • RET fusion • ALK fusion","tags":["HER-2 • BRAF • ALK • RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • BRAF V600 • RET fusion • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • carboplatin • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/12/2017","start_date":" 05/12/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2023-12-04"},{"id":"a54c5bf1-77a7-4e44-bb57-e245104dfd72","acronym":"","url":"https://clinicaltrials.gov/study/NCT03780517","created_at":"2021-01-18T18:41:54.388Z","updated_at":"2024-07-02T16:35:31.196Z","phase":"Phase 1","brief_title":"Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors","source_id_and_acronym":"NCT03780517","lead_sponsor":"Boston Pharmaceuticals","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zeteletinib (BOS-172738)"],"overall_status":"Completed","enrollment":" Enrollment 117","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 09/26/2023","primary_completion_date":" 09/26/2023","study_txt":" Completion: 09/26/2023","study_completion_date":" 09/26/2023","last_update_posted":"2023-10-30"},{"id":"c7e9b9c9-d4ce-4d93-91cb-690df0a318f7","acronym":"Delivir","url":"https://clinicaltrials.gov/study/NCT05788926","created_at":"2023-03-29T14:03:17.793Z","updated_at":"2024-07-02T16:35:32.334Z","phase":"Phase 1","brief_title":"A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)","source_id_and_acronym":"NCT05788926 - Delivir","lead_sponsor":"Transgene","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • ALK • RET • ROS1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • HER-2 mutation • RET fusion • RET mutation • ROS1 fusion • RET rearrangement • KRAS G12","tags":["EGFR • HER-2 • PD-L1 • KRAS • ALK • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • HER-2 mutation • RET fusion • RET mutation • ROS1 fusion • RET rearrangement • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TG6050"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/05/2023","start_date":" 04/05/2023","primary_txt":" Primary completion: 10/30/2024","primary_completion_date":" 10/30/2024","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2023-10-20"}]